Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
Trial details
- Registry ID
- NCT05303064
- Phase
- Phase 3
The FDA approved Olanzapine on 30 Sep 1996.
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I DisorderNCT05303064 | Alkermes, Inc. | Phase 3 | Recruiting | 2027-12Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 1996-09-30Day | Olanzapine | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA020592", "applicant_as_listed_by_fda": "CHEPLAPHARM", "brand_names": ["ZYPREXA"], "active_ingredients": ["OLANZAPINE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "19960930", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |